These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23588332)

  • 1. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
    Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
    Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
    Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
    Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
    Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
    Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
    Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
    Shi HY; Yan J; Zhu WH; Yang GP; Tan ZR; Wu WH; Zhou G; Chen XP; Ouyang DS
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1131-6. PubMed ID: 20669013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
    Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
    Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of the triazole antifungal agent voriconazole.
    Mikus G; Scholz IM; Weiss J
    Pharmacogenomics; 2011 Jun; 12(6):861-72. PubMed ID: 21692616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
    Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
    Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.
    Matsumoto K; Ikawa K; Abematsu K; Fukunaga N; Nishida K; Fukamizu T; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    Int J Antimicrob Agents; 2009 Jul; 34(1):91-4. PubMed ID: 19261446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
    Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
    Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms.
    Lemaitre F; Barbaz M; Scailteux LM; Uhel F; Tadié JM; Verdier MC; Bellissant E
    Drug Metab Pharmacokinet; 2013; 28(5):439-41. PubMed ID: 23545593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
    Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
    Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.
    Shoji K; Hikino K; Saito J; Matsui T; Utano T; Takebayashi A; Tomizawa D; Kato M; Matsumoto K; Ishikawa T; Kawai T; Nakamura H; Miyairi I; Terao C; Mushiroda T
    J Infect Chemother; 2024 Dec; 30(12):1280-1288. PubMed ID: 38897411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
    Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.
    Autmizguine J; Krajinovic M; Rousseau J; Théorêt Y; Litalien C; Marquis C; Tapiéro B; Ovetchkine P
    Pharmacogenomics; 2012 Dec; 13(16):1961-5. PubMed ID: 23215888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
    Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
    Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.